G Medical Innovations (ASX:GMV) secured Taiwan FDA approval

Company News

by Katrina Bullock

Medical product provider, G Medical Innovations Holdings (ASX:GMV) has secured regulatory approval from the Taiwan Food and Drug Administration for its Prizma device.

The ‘Prizma’ allows consumers to turn their smartphone into a mobile medical monitor to measure vital signs.

Commercial negotiations can now commence with G Medical’s existing distribution and service partner, FCL. G Medical also intends to explore additional partnerships within Taiwan.

CEO and Executive Director Dr Yacov Geva says “[b]eing granted approval by the Taiwan Food and Drug Administration is a tremendous achievement for G Medical. The process has involved rigorous testing, which has outlined the safety and effectiveness of the Prizma device.”

Shares in G Medical Innovations Holdings (ASX:GMV) are trading 34.6 per cent higher at 18 cents.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.